Research library

Key finding

Daily eight-hour subcutaneous Kisspeptin-10 infusions maintained higher gonadotropin secretion across 12 days, while acute administration also increased LH, FSH, and testosterone in healthy men.

Key finding

Intravenous Kisspeptin-10 produced a rapid, dose-dependent rise in LH. Continuous infusion also increased testosterone, LH pulse frequency, and pulse size in healthy men.

Key finding

In men with low sexual desire, Kisspeptin-54 altered activity in sexual-processing brain networks and was associated with increased physiological arousal and several desire-related measures.

Key finding

At the tested intravenous doses, Kisspeptin-10 and Kisspeptin-54 generated broadly similar gonadotropin responses in healthy men, while GnRH produced the stronger response.

Key finding

In a small proof-of-concept study, Kisspeptin-10 increased LH secretion and pulse frequency in men with type 2 diabetes and mild biochemical hypogonadism, alongside higher testosterone.

Key finding

Successful reproduction is a fundamental physiological process that relies on the integration of sensory cues of attraction with appropriate emotions and behaviors and the reproductive axis.

Key finding

Kisspeptin altered resting-state connectivity in brain networks involved in sexual and emotional processing, with several connectivity changes correlating with psychometric responses.

Key finding

Triggering final oocyte maturation with kisspeptin is a novel therapeutic option to enable the use of fresh embryo transfer even in the woman at high risk of OHSS.

Key finding

Oocyte maturation occurred in 95% of participants, with no moderate, severe, or critical ovarian hyperstimulation syndrome reported in the study.

Key finding

Kisspeptin is a novel therapeutic target for infertility.

Key finding

Acute administration of kisspeptin to women with infertility due to HA potently stimulates gonadotropin release, but chronic administration of kisspeptin results in desensitization to its effects on gonadotropin release.

Key finding

Elevation of plasma concentrations of kisspeptin in human males significantly increases circulating LH, FSH, and testosterone levels.

Key finding

In five women with hypothalamic amenorrhoea, Kisspeptin-54 temporarily increased LH pulse frequency and pulse secretory mass, with the strongest dose differing by participant.

Key finding

Triggering oocyte maturation by inducing endogenous gonadotrophin release is preferable to the use of exogenous hCG in women at high risk of OHSS.

Key finding

In women with low sexual desire, Kisspeptin-54 modulated brain responses to sexual and attraction stimuli, with activity changes linked to lower aversion and baseline distress measures.

Key finding

BACKGROUNDKisspeptin is a key regulator of hypothalamic gonadotropin-releasing hormone (GnRH) neurons and is essential for reproductive health.

Key finding

In this first report of kisspeptin administration to pediatric subjects to our knowledge, children with delayed/stalled puberty showed a wide range of responses, with some showing a robust response and others showing little to no response.

Key finding

In healthy men, Kisspeptin increased limbic activity in response to sexual and couple-bonding stimuli, with responses linked to reward, drive, mood, and sexual-aversion measures.

Key finding

The ability of kisspeptin to stimulate a GnRH-induced LH pulse correlates with the presence of endogenous LH pulses.

Key finding

Natural peptides displaying agonist activity on the orphan G protein-coupled receptor GPR54 were isolated from human placenta.